<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>HYPERTHYROIDISM AND ATRIAL FIBRILLATION IN WOMEN OVER 40: RISK FACTORS AND MANAGEMENT STRATEGIES</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Samandar</mods:namePart><mods:namePart type="family">Ostonov</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Fayzi</mods:namePart><mods:namePart type="family">Nasullayev</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Hyperthyroidism, characterized by excessive thyroid hormone production, is a well-established risk factor for atrial fibrillation (AF), particularly in women over 40. This article reviews the pathophysiological mechanisms, epidemiological data, and evidence-based management approaches for AF in hyperthyroid patients, with a focus on middle-aged and older women. We analyze key studies and clinical guidelines to provide a comprehensive overview of this critical cardiovascular-endocrine interaction.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-04-19</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Research Science and Innovation House</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>